Johnson & Johnson Executive Sells Shares Amid Strong Stock Performance
A top executive at Johnson & Johnson (JNJ) recently sold nearly half of her stake in the company, raising questions about insider sentiment despite a strong stock performance. Vanessa Broadhurst, EVP of Global Corporate Affairs, sold $5.8 million worth of shares on July 20, which some analysts attribute to profit-taking rather than concern. Johnson & Johnson has been repositioning itself by spinning off lower-growth segments like consumer health and orthopedics into separate entities such as DePuy Synthes. The company is now focused on high-growth areas in pharmaceuticals with a robust pipeline including drugs for psoriasis, Crohn's disease, depression, multiple myeloma, lung cancer, and surgical robotics. Recent financial results show strong performance across key franchises like oncology, where revenue grew 17.3% year-over-year led by Darzalex and Carvykti. However, some older drugs such as Stelara and Imbruvica are facing declining sales due to competition from biosimilars and newer treatments.
Tickers: $JNJ
Topics: corporate strategy executive sales JNJ stock Johnson & Johnson